Collection of tissue samples from patients with tumors and their family members
Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members
This study is collecting tissue and blood samples from patients with tumors and their family members to help researchers learn more about these diseases and improve treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 2 Years to 100 Years |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT00071045 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect biological samples from patients with solid tumors or blood disorders, as well as their HLA-compatible family members. The samples, which may include blood, bone marrow, and tissue, will be used for research to better understand these diseases and evaluate treatment effectiveness. The study will also facilitate the collection of samples from potential stem cell donors for transplantation research. There is no primary endpoint, as the focus is on sample collection and analysis.
Who should consider this trial
Good fit: Ideal candidates include patients aged 2 years or older with solid tumors or blood disorders, as well as HLA-compatible family members who may serve as stem cell donors.
Not a fit: Patients who do not have a solid tumor or blood disorder, or those who are not HLA-compatible family members of eligible patients, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of cancer and blood disorders, leading to improved treatment strategies and potential new therapies.
How similar studies have performed: Other studies involving tissue sample collection for cancer research have shown success in advancing understanding and treatment options, indicating that this approach is well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH protocol. OR The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a protocol at the NIH Clinical Center. OR The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation. OR The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel to the NIH clinical center, but is referred for participation through their home health care provider. The subject or the subject's Legally Authorized Representative (LAR) is able to understand the investigational nature of the study and provide informed consent after initial counseling by an AI. Separate consent forms for interventional or surgical procedures will be obtained after explanation of the specific procedure. Age 2 years and older (no upper limit) EXCLUSION CRITERIA: Subjects or LAR unable to comprehend the investigational nature of the protocol. Age less than 2 years
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Richard W Childs, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
- Study coordinator: Bretagne C Cowling, R.N.
- Email: bretagne.cowling@nih.gov
- Phone: (301) 827-3479
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.